IN8bio, Inc. (INAB)
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
$15.43M
Mr. Tai-Wei Ho
26.00
New York, NY
Jul 30, 2021
-0.40
$-0.82
2.15
2.66
-852.67%
-0.45
0.00
1.06
4.01
2.66
-142.06%
-173.12%
Similar stocks (12)
Annexon, Inc.
ANNX
Anixa Biosciences, Inc.
ANIX
INmune Bio, Inc.
INMB
Lantern Pharma Inc.
LTRN
Reviva Pharmaceuticals Holdings, Inc.
RVPH
Gain Therapeutics, Inc.
GANX
Cue Biopharma, Inc.
CUE
TFF Pharmaceuticals, Inc.
TFFP
Windtree Therapeutics, Inc.
WINT
CNS Pharmaceuticals, Inc.
CNSP
Palisade Bio, Inc.
PALI
Allarity Therapeutics, Inc.
ALLR
ETF Exposure (6)
iShares Micro-Cap ETF
IWC
0.00202%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (12)
Annexon, Inc.
ANNX
Anixa Biosciences, Inc.
ANIX
INmune Bio, Inc.
INMB
Lantern Pharma Inc.
LTRN
Reviva Pharmaceuticals Holdings, Inc.
RVPH
Gain Therapeutics, Inc.
GANX
Cue Biopharma, Inc.
CUE
TFF Pharmaceuticals, Inc.
TFFP
Windtree Therapeutics, Inc.
WINT
CNS Pharmaceuticals, Inc.
CNSP
Palisade Bio, Inc.
PALI
Allarity Therapeutics, Inc.
ALLR
ETF Exposure (6)
iShares Micro-Cap ETF
IWC
0.00202%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%